Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06423560
Status:
COMPLETED
Last Update Posted:
2024-05-21
First Post:
2024-05-16
Brief Title:
Pulmonary Fibrosis After Severe COVID-19 Pneumonia
Sponsor:
IRCCS San Raffaele
Organization:
IRCCS San Raffaele
Study Overview
Official Title:
Evaluation of Pulmonary Fibrosis After Severe Interstitial Pneumonia Due to COVID-19 SARS-CoV-2
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SPIFFERO
Brief Summary:
Patients discharged after hospitalization for COVID-19 pneumonia were retrospectively selected by radiologically established criteria that at admission presented at chest computed tomography CT i normal lung parenchyma 50 of total lung volume andor ii area of lung consolidation 10 All At discharge and after 9 months all subjects underwent cardiological evaluation echocardiogram pulmonary function tests PFT both atby 3 and by 12 months after discharge Chest CT was performed by 12 months after discharge and chest CT Specifically the magnitude of pulmonary involvement between baseline and follow-up was considered the primary endpoint of this study Secondary endpoints of the study were results of respiratory function testing echocardiographic parametersparameters and persistence of symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None